Local adipose tissue renin-angiotensin system

Current Hypertension Reports

Volumn 10, Issue 2, 2008, Pages 93-98

  Cassis, Lisa A ^a   Police, Sara B ^b   Yiannikouris, Frederique ^b   Thatcher, Sean E ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RENIN; RENIN INHIBITOR; SERUM AMYLOID A; SIBUTRAMINE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; ACETYLCHOLINESTERASE;

ABDOMINAL OBESITY; ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ADIPOSE TISSUE; AMINO ACID SUBSTITUTION; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; CYTOKINE RELEASE; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; INTRAABDOMINAL FAT; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION; METABOLISM; SUBCUTANEOUS FAT;

ACETYLCHOLINESTERASE; ADIPOCYTES; ADIPOSITY; HUMANS; HYPERTENSION; OBESITY; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SUBCUTANEOUS FAT;

EID: 52049090409     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0019-9     Document Type: Review

References (43)

1. Bays H, Rodbard HW, Schorr AB, Gonzalez-Campoy JM: Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 2007, 9:259-271.
2. Cassis LA, Saye J, Peach MJ: Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988, 11:591-596.
3. Campbell DJ, Habener JF: Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 1987, 121:1616-1626.
4. Cassis LA, Lynch KR, Peach MJ: Localization of angiotensinogen messenger RNA in rat aorta. Circ Res 1988, 62:1259-1262.
5. Cassis LA: Fat cell metabolism: insulin, fatty acids, and renin. Curr Hypertens Rep 2000, 2:132-138.
6. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA: Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007, 292: E1280-E1287.
7. Kim S, Soltani-Bejnood M, Quignard-Boulange A, et al.: The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J Biomed Biotechnol 2006, 2006:27012.
8. Goossens GH, Jocken JW, Blaak EE, et al.: Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Hypertension 2007, 49:542-547.
9. Goossens GH, McQuaid SE, Dennis AL, et al.: Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 2006, 571:451-460.
10. Li Y, Jain S, Patil S, Kumar A: A haplotype of angiotensinogen gene that is associated with essential hypertension increases its promoter activity in adipocytes. Vascul Pharmacol 2006, 44:29-33.
11. Jain S, Tang X, Narayanan CS, et al.: Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans. J Biol Chem 2002, 277:36889-36896.
12. Dickson ME, Zimmerman MB, Rahmouni K, Sigmund CD: The -20 and -217 promoter variants dominate differential angiotensinogen haplotype regulation in angiotensinogen-expressing cells. Hypertension 2007, 49:631-639.
13. Kotani K, Sakane N, Saiga K, et al.: The uncoupling protein-1 gene -3826A/G polymorphism and hypertension in Japanese subjects. Clin Chem Lab Med 2007, 45:1186-1189.
14. Achard V, Boullu-Ciocca S, Desbriere R, et al.: Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol, 2007, 292:R274-R282.
15. Bujak-Gizycka B, Madej J, Wolkow PP, et al.: Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). J Physiol Pharmacol 2007, 58:529-540.
16. Cassis L, Gupte M, Boustany C, et al.: Novel expression of ACE2 in adipose tissue and regulation by PPARγ ligands and by high fat diets [abstract CHBRPP142]. Paper presented at the Council for High Blood Pressure Research Conference. San Antonio, TX; October 4-7, 2006.
17. Ailhaud G: Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure. Ann N Y Acad Sci 1999, 892:127-133.
18. Brucher R, Cifuentes M, Acuna MJ, et al.: Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity (Silver Spring) 2007, 15:1643-1646.
19. Skurk T, van Harmelen V, Hauner H: Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 2004, 24:1199-1203.
20. Matsushita K, Wu Y, Okamoto Y, et al.: Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006, 48:1095-1102.
21. Sarzani R, Marcucci P, Salvi F, et al.: Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes (Lond) 2007.
22. Weisberg SP, McCann D, Desai M, et al: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
23. Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
24. Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605-1612.
25. Harrison D, Griendling KK, Landmesser U, et al.: Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91:7A-11A.
26. Tsuchiya K, Yoshimoto T, Hirono Y, et al.: Angiotensin II induces monocyte chemoattractant protein-1 expression via nuclear factor-kappa B-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006, 291:E771-E778.
27. Kurata A, Nishizawa H, Kihara S, et al.: Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006, 70:1717-1724.
28. Yvan-Charvet L, Bobard A, Bossard P, et al.: In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2007, 27:1340-1345.
29. Iwai M, Chen R, Imura Y, Horiuchi M: TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007, 20:579-586.
30. Zorad S, Dou JT, Benicky J, et al.: Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006, 552:112-122.
31. Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20-34.
32. Giacchetti G, Faloia E, Mariniello B, et al.: Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002, 15:381-388.
33. Shimabukuro M, Tanaka H, Shimabukuro T: Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007, 25:841-848.
34. Engeli S, Bohnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
35. Garg A, Fleckenstein JL, Peshock RM, Grundy SM: Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 1992, 75:358-361.
36. Abate N, Garg A: Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog Lipid Res 1995, 34:53-70.
37. Soltis EE, Cassis LA: Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens 1991, 13:277-296.
38. Takemori K, Gao YJ, Ding L, et al.: Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 2007, 49:365-372.
39. Segura J, Ruilope LM: Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007, 10:1151-1155.
40. Kintscher U, Bramlage P, Paar WD, et al.: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post-authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007, 6:12.
41. Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115:1991-1998.
42. Schindler C, Bramlage P, Thoenes M, et al.: Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs. Clin Drug Investig 2007, 27:707-717.
43. Bestermann W, Houston MC, Basile J, et al.: Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005, 329:292-305.